Vernalis Research Limited

Allan Fletcher

Robin Gerald Shepherd

Scott Murray Weiss

Lars Jacob Stray Knutsen

Richard H P Porter

Use of (&plus;)-(11R,2&prime;S)-&agr;-2-piperidinyl-2,8-bis(trifluoromethyl)-4-quinolinemethanol or a pharmaceutically acceptable salt thereof substantially free of its (&minus;)-enantiomer in the manufacture of a medicament having reduced side-effect compared to the racemic (&plusmn;)-(R*,S*)-&agr;-2-piperidinyl-2,8-bis(trifluoromethyl)-4-quinolinemethanol for treating or preventing malaria in a subject. A method of treating or preventing malaria with reduced side-effects comprising administration of (&plus;)-(11R,2&prime;S)-&agr;-2-piperidinyl-2,8-bis(trifluoromethyl)-4-quinolinemethanol or a pharmaceutically acceptable salt thereof substantially free of its (&minus;)-enantiomer.

Use of (&plus;)mefloquine for the treatment of malaria

The present invention relates to the use of (&plusmn;)-R*,S*)-alpha-2-piperidnyl-2,8-bis(trifluoromethyl)-4-quinolinemthanol and in particular (&minus;)-(11S,2&prime;R)-alpha-2-piperidnyl-2,8-bis(trifluoromethyl)-4-quinolinemthanol in the treatment of disorders in which the reduction of purinergic neurotransmission could be beneficial. The invention relates in particular to adenosine receptors, and particularly adenosine A2a receptors and to the treatment of movement disorders such as Parkinson's disease.

Growing community of inventors

Cleveland, United Kingdom

Allan Fletcher